Amended Form 10 Reveals Going Concern, $4.3M Liabilities, and 99.99% Insider Voting Control at Biomolecular Life Holdings
BIOM filed a Corporate Governance and Compliance on light trading volume (0.3× avg).
Summary
Biomolecular Life Holdings' amended Form 10 reveals a going concern warning, no cash, $4.3M in liabilities, and a single insider controlling 99.99% of votes while also running the company's only client.
Key Events · Corporate Governance and Compliance · BIOM
-
Going Concern Warning
The auditor expresses substantial doubt about the company's ability to continue as a going concern. As of June 30, 2026, there is no cash on hand, $4.3M in current liabilities, and a $116.8M accumulated deficit.
-
99.99% Insider Voting Control
Jessika Contreras, sole director and CEO, controls 958.6 billion votes (99.99% of total) through 95,858,282 shares of super-voting Series A Preferred Stock held in a family trust. Each preferred share carries 10,000 votes.
-
Related-Party Revenue Dependence
The only revenue source is a 15% marketing fee from Biomolecular Life LLC, a company also managed by Contreras. The agreement was not negotiated at arm's length and can be terminated by either party on 30 days' notice.
-
Derivative Liability Surge
Derivative liability increased from $1.22M to $2.24M in six months, driven by a $1.07M non-cash mark-to-market loss on convertible notes with deep-discount conversion features (25-75% discounts to market price).
Analysis · BIOM · Life Sciences
This Amendment No. 1 to the Form 10 registration statement adds audited financial statements and material disclosures that were absent from the original August 25 filing. As of June 30, 2026, the company has no cash, $4.3 million in current liabilities, and a $116.8 million accumulated deficit. The auditor's report expresses substantial doubt about the company's ability to continue as a going concern. A single individual, Jessika Contreras, controls 99.99% of voting power through super-voting Series A Preferred Stock held in a family trust, while simultaneously serving as sole officer and director of both the company and its only client. The derivative liability more than doubled to $2.24 million in six months, driven by a $1.07 million non-cash mark-to-market loss. The company's only revenue source is a 15% marketing fee from a related-party client that can terminate the agreement on 30 days' notice.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 40.4% of the 1069 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIOM was trading at $0.47 on OTC in the Life Sciences sector, with a market capitalization of approximately $495.7K. The 52-week trading range was $0.02 to $2.25. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.